This is a preview of subscription content, log in via an institution to check access.
References
Mislick K, et al. Comparative cost-effectiveness analysis of mammostrat versus oncotype Dx to guide treatment decisions with adjuvant chemotherapy in early-stage breast cancer. 36th Annual San Antonio Breast Cancer Symposium : abstr. P6-07-08, 10 Dec 2013. Available from: URL: http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_429
Saghatchian M, et al. Cost-effectiveness of molecular profiling for adjuvant decision making for patients with node negative breast cancers. 36th Annual San Antonio Breast Cancer Symposium : abstr. P6-07-03, 10 Dec 2013. Available from: URL: http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_881
Rights and permissions
About this article
Cite this article
Mammostrat genotyping worth considering for early-stage BC. PharmacoEcon Outcomes News 695, 6 (2014). https://doi.org/10.1007/s40274-014-1003-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1003-z